Letter to the Editor doi:10.1093/eurheartj/ehm140

Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM: reply The ESTEEM trial was a phase II study evalu-ating the efficacy and safety of treatment with the first available oral direct thrombin inhibitor ximelagatran together with aspirin, when compared with aspirin only, after a recent myocardial infarction.1 In a subgroup of 518 (out of 1883) patients, we measured markers of coagulation activity, i.e. prothrom-bin fragment 1 þ 2 (F1 þ 2) and D-dimer, in serial samples obtained during and afte